---
layout: splash
title: 종근당 (185750)
excerpt: 종근당의 최근 공시, 수익률, 주요 재무/기술 지표
header:
  overlay_color: "#333"
  show_overlay_excerpt: false
categories:
- KOSPI
- P:의약품
keywords: 종근당, 185750
---

| **종가** | **전일대비** | **업종** | **PER** | **PBR** | **DIV** |
| -------: | -----------: | -------: | ------: | ------: | ------: |
| 103,200 | <span style="color: tomato">0.6<small>%</small></span> | P:의약품 | 6.5 | 1.6 | 1.1<small>%</small> |

<!-- more -->


> **기업 개요**<a id="company"></a>

| <span style="white-space:nowrap;">**섹터**</span> | P:의약품 / 의약품 제조업 |
| <span style="white-space:nowrap;">**산업**</span> | 딜라트렌, 리피로우 |
| <span style="white-space:nowrap;">**상장**</span> | KOSPI / 2013년 12월 6일 상장 / 12월 결산 |
| <span style="white-space:nowrap;">**대표자**</span> | 김영주 |
| <span style="white-space:nowrap;">**홈페이지**</span> | [http://www.ckdpharm.com](http://www.ckdpharm.com){:target="_blank"} |


> **최근 7일 DART 신규 공시**<a id="dart"></a>

| **일자** |      | **보고서명** |
| :------- | :--- | :----------- |
| 05&#x2011;10 | | [투자판단관련주요경영사항              (탈모 치료제로 개발중인 CKD-843의 식약처(MFDS) 제3상 임상시험 계획 승인 신청)](https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20240510800916){:target="_blank"} |


> **주가 흐름**<a id="price"></a>

![185750](/stock/images/185750.png){: .align-center}


> **주요 가격 변동 지표**<small>[^fn_price_metric]</small>

| **종가** | **전일대비** | **5일** | **20일** | **60일** | **120일** |
| -------: | -----------: | ------: | -------: | -------: | --------: |
| 103,200 | <span style="color: tomato">0.6<small>%</small></span> | <span style="color: cornflowerblue">-0.3<small>%</small></span> | <span style="color: cornflowerblue">-0.1<small>%</small></span> | <span style="color: cornflowerblue">-6.9<small>%</small></span> | <span style="color: cornflowerblue">-7.4<small>%</small></span> |
| **1년** | **편차** | **샤프** | **MDD** | **AvDD** | **MARr** |
| <span style="color: tomato">25.5<small>%</small></span> | 42.9<small>%</small> | 0.60 | -25.5<small>%</small> | -9.3<small>%</small> | -1.0 |


> **주요 재무 지표**<small>[^fn_finance_metric]</small>

| **업종**<small>[^fn_sector_abbr]</small> | **PER** | **PBR** | **DIV** | **평가**<small>[^fn_finance_basic_tags]</small> |
| :--------------------------------------- | ------: | ------: | ------: | ----------------------------------------------: |
| P:의약품 | 6.5 | 1.6 | 1.1<small>%</small> | - |



{% include /commons/ads/adsense.html %}

> **세부 재무/투자 정보 제공 사이트**

| [네이버](https://m.stock.naver.com/domestic/stock/185750/finance/summary){:target="_blank"}<sup><small>모바일</small></sup> | [네이버](https://finance.naver.com/item/coinfo.naver?code=185750){:target="_blank"} | [FnGuide](https://comp.fnguide.com/SVO2/ASP/SVD_Invest.asp?gicode=A185750&MenuYn=Y){:target="_blank"} |
| :---: | :---: | :---: |
| [와이즈리포트](https://comp.wisereport.co.kr/company/c1040001.aspx?cmp_cd=185750){:target="_blank"} | [밸류라인](https://www.valueline.co.kr/finance/summary/185750){:target="_blank"} | [한국경제](https://markets.hankyung.com/stock/185750/financial-summary){:target="_blank"} |


> **주요 기술 지표**<small>[^fn_tech_metric]</small>


![185750](/stock/images/185750_tech.png){: .align-center}

| **기술 지표** | **1년** | **편차** | **샤프** | **MDD** | **AvDD** |
| :------------ | ------: | -----------: | -------: | ------: | -------: |
| 거치식 | 25.5<small>%</small> | 42.9<small>%</small> | 0.60 | -25.5<small>%</small> | -9.3<small>%</small> |
| 적립식[^fn_tech_metric_dca] | 8.2<small>%</small> | 42.5<small>%</small> | 0.19 | -30.2<small>%</small> | -10.5<small>%</small> |
| Sig. M[^fn_tech_metric_sigm] | 19.3<small>%</small> | 37.4<small>%</small> | 0.52 | -16.3<small>%</small> | -6.6<small>%</small> |
| SMA<small><sub>(5)</sub></small>[^fn_tech_metric_sma_i] | 4.5<small>%</small> | 35.5<small>%</small> | 0.13 | -26.1<small>%</small> | -11.1<small>%</small> |
| SMA<small><sub>(20)</sub></small>[^fn_tech_metric_sma_i] | 9.0<small>%</small> | 37.7<small>%</small> | 0.24 | -25.3<small>%</small> | -8.7<small>%</small> |
| SMA<small><sub>(60)</sub></small>[^fn_tech_metric_sma_i] | 31.6<small>%</small> | 37.0<small>%</small> | 0.86 | -17.9<small>%</small> | -7.8<small>%</small> |
| SMA<small><sub>(120)</sub></small>[^fn_tech_metric_sma_i] | 17.3<small>%</small> | 39.0<small>%</small> | 0.44 | -24.3<small>%</small> | -9.8<small>%</small> |
| SMA<small><sub>(240)</sub></small>[^fn_tech_metric_sma_i] | 18.5<small>%</small> | 41.3<small>%</small> | 0.45 | -25.5<small>%</small> | -9.5<small>%</small> |
| MACD[^fn_tech_metric_macd] | -9.4<small>%</small> | 35.3<small>%</small> | -0.27 | -26.7<small>%</small> | -10.0<small>%</small> |


> **주가 흐름 유사 종목**<a id="corr"></a><small>[^fn_corr_long]</small>

![185750](/stock/images/185750_corr.png){: .align-center}

|       | [삼성에스디에스](/018260/) | [한올바이오파마](/009420/) | [롯데웰푸드](/280360/) |
| :---: | :------------------------------------: | :------------------------------------: | :------------------------------------: |
|       | [대웅](/003090/) | [안랩](/053800/) | [DGB금융지주](/139130/) |


> **가상 레버리지 상품에 투자했다면**<a id="2x"></a><small>[^fn_lev]</small>

![185750](/stock/images/185750_2x.png){: .align-center}


> **관련 정보**

- [P:의약품 업종 목록](/stats/sector/kospi_업종_의약품_종목/){: .btn .btn--info}

{% include commons/footnotes.md %}